The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family

European Journal of Pharmacology

Volumn 538, Issue 1-3, 2006, Pages 39-42

  Gibson, Lucien C D ^a   Hastings, Stuart F ^a   McPhee, Ian ^a   Clayton, Robert A ^a   Darroch, Claire E ^a   Mackenzie, Alison ^a   MacKenzie, Fiona L ^a   Nagasawa, Michiaki ^b   Stevens, Patricia A ^a   MacKenzie, Simon J ^a  

^a Scottish Biomedical   (United Kingdom)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Ibudilast; Neurological disease; Phosphodiesterase; Respiratory disease

Indexed keywords

IBUDILAST; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE 11; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG; CYCLIC AMP; CYCLIC GMP; ISOENZYME; PYRIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; ASTHMA; CELL CYCLE; CEREBROVASCULAR ACCIDENT; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; ANIMAL; ARMYWORM; CELL LINE; ENZYME SPECIFICITY; GENETICS; HUMAN; HYDROLYSIS; KINETICS; METABOLISM;

ANIMALS; CELL LINE; CYCLIC AMP; CYCLIC GMP; HUMANS; HYDROLYSIS; ISOENZYMES; KINETICS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIDINES; SPODOPTERA; SUBSTRATE SPECIFICITY;

EID: 33747093820     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.053     Document Type: Article

References (32)

1. Bourtchouladze R., Lidge R., Catapano R., Stanley J., Gossweiler S., Romashko D., Scott R., and Tully T. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase: 4. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10518-10522
2. Dyke H.J., and Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs 11 (2002) 1-13
3. Feng J., Misu T., Fujihara K., Sakoda S., Nakatsuji Y., Fukaura H., Kikuchi S., Tashiro K., Suzumura A., Ishii N., Sugamura K., Nakashima I., and Itoyama Y. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult. Scler. 10 (2004) 494-498
4. Fujishige K., Kotera J., and Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur. J. Biochem. 266 (1999) 1118-1127
5. Fukuyama H., Kimura J., Yamaguchi S., Yamauchi H., Ogawa M., Doi T., Yonekura Y., and Konishi J. Pharmacological effects of ibudilast on cerebral circulation: a PET study. Neurol. Res. 15 (1993) 169-173
6. Kagitani-Shimono K., Mohri I., Fujitani Y., Suzuki K., Ozono K., Urade Y., and Taniike M. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J. Neuroinflamm. 2 (2005) 10
7. Kishi Y., Ohta S., Kasuya N., Tatsumi M., Sawada M., Sakita S., Ashikaga T., and Numano F. Ibudilast modulates platelet-endothelium interaction mainly through cyclic GMP-dependent mechanism. J. Cardiovasc. Pharmacol. 36 (2000) 65-70
8. Lugnier, C., in press. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacology and Therapeutics.
9. Mizuno T., Kurotani T., Komatsu Y., Kawanokuchi J., Kato H., Mitsuma N., and Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 46 (2004) 404-411
10. Murashima S., Nagami K., Kawahara N., and Sugisaki H. Inhibitory effect of ibudilast (KC-404) on cyclic nucleotide phosphodiesterases. Jpn. Pharmacol. Ther. 26 (1998) 41-45
11. Nagai H., Iwamoto T., Nishiyori T., Takizawa T., Tsuchiya H., and Koda A. Pharmacological studies on newly synthesized anti-allergic agents, 2-methyl-3-piperidino-beta-propionaphtone hydrochloride (KZ-111) and 3-isobutyryl-2-isopropylpyrazole-[1,5-a] pyridine (KC-404). Jpn. J. Pharmacol. 33 (1983) 1215-1223
12. Nishino K., Hara S., and Irikura T. Effect of KC-404 on allergic reactions types I-IV. Nippon Yakurigaku Zasshi 83 (1984) 291-299
13. Ohashi M., Ohkubo H., Kito J., and Nishino K. A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation. Arch. Int. Pharmacodyn. Ther. 283 (1986) 321-334
14. Ohashi M., Uno T., and Nishino K. Effect of ibudilast, a novel antiasthmatic agent, on anaphylactic bronchoconstriction: predominant involvement of endogenous slow reacting substance of anaphylaxis. Int. Arch. Allergy Immunol. 101 (1993) 288-296
15. Rodefer J.S., Murphy E.R., and Baxter M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21 (2005) 1070-1076
16. Soderling S.H., Bayuga S.J., and Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7071-7076
17. Souness J.E., Villamil M.E., Scott L.C., Tomkinson A., Giembycz M.A., and Raeburn D. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br. J. Pharmacol. 111 (1994) 1081-1088
18. Suzumura A., Ito A., Yoshikawa M., and Sawada M. Ibudilast suppresses TNFα production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 837 (1999) 203-212
19. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19 (1999) 610-618
20. Takuma K., Lee E., Enomoto R., Mori K., Baba A., and Matsuda T. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br. J. Pharmacol. 133 (2001) 841-848
21. Takuma K., Phuagphong P., Lee E., Mori K., Baba A., and Matsuda T. Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J. Biol. Chem. 276 (2001) 48093-48099
22. Thompson W.J., and Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10 (1971) 311-316
23. Tominaga Y., Nakamura Y., Tsuji K., Shibata T., and Kataoka K. Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons. Clin. Exp. Pharmacol. Physiol. 23 (1996) 519-523
24. Underwood D.C., Kotzer C.J., Bochnowicz S., Osborn R.R., Luttmann M.A., Hay D.W., and Torphy T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270 (1994) 250-259
25. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., and Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13217-13221
26. Wayman C., Phillips S., Lunny C., Webb T., Fawcett L., Baxendale R., and Burgess G. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int. J. Impot. Res. 17 (2005) 216-223
27. Yoshioka A., Shimizu Y., and Hirose G. Ibudilast prevents oligodendroglial excitotoxicity. No To Shinkei 49 (1997) 1015-1020
28. Yoshioka A., Shimizu Y., Hirose G., Kitasato H., and Pleasure D. Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity. J. Neurochem. 70 (1998) 2416-2423
29. Yoshioka A., Yamaya Y., Saiki S., Kanemoto M., Hirose G., and Pleasure D. Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial line. J. Neurochem. 74 (2000) 633-640
30. Yoshioka M., Suda N., Mori K., Ueno K., Itoh Y., Togashi H., Matsumoto M., Togashi H., and Matsumoto M. Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia. Pharmacol. Res. 45 (2002) 305-311
31. Zhang B., Yang L., Konishi Y., Maeda N., Sakanaka M., and Tanaka J. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 42 (2002) 262-269
32. Zhang H.T., Huang Y., Jin S.L., Frith S.A., Suvarna N., Conti M., and O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27 (2002) 587-595